ZymoGenetics

ZymogeneticsAsViewedFromLakeUnion

ZymoGenetics, Inc. was a biopharmaceutical company based in Seattle, Washington. Founded in 1981 by a group of scientists from the University of Washington, it was one of the oldest biotechnology companies in the USA, focusing on the development and commercialization of therapeutic proteins. Originally an independent entity, ZymoGenetics became a subsidiary of Bristol-Myers Squibb in 2010.

History

ZymoGenetics was established to explore the rapidly evolving field of recombinant DNA technology. The company aimed to harness this technology to develop innovative treatments for various diseases. Over the years, ZymoGenetics made significant contributions to the field of biopharmaceuticals, focusing on areas such as autoimmunity, inflammation, and hemostasis.

In 2010, ZymoGenetics was acquired by Bristol-Myers Squibb for approximately $885 million, a move that aimed to bolster Bristol-Myers Squibb's pipeline with ZymoGenetics' promising experimental drugs and research capabilities in biologics.

Products and Research

ZymoGenetics' research efforts were primarily focused on protein therapeutics. One of its notable products was Recothrom, a recombinant version of human thrombin, used to control bleeding during surgery. This product exemplified the company's approach to developing biologics that could offer alternatives to traditional treatments.

The company's pipeline also included experimental treatments for autoimmune diseases and cancer, reflecting the broader industry trend towards targeted therapies that could offer improved efficacy and reduced side effects compared to conventional treatments.

Facilities

ZymoGenetics was headquartered in the iconic Lake Union Steam Plant building in Seattle, a landmark that symbolized the company's blend of historical roots and modern scientific ambition. The facility housed the company's research laboratories, administrative offices, and manufacturing operations, serving as a hub for its various activities.

Impact and Legacy

The acquisition of ZymoGenetics by Bristol-Myers Squibb marked the end of its independence but not its influence. The company's research and products continued to contribute to the biopharmaceutical industry, and its legacy lived on through its contributions to science and medicine. ZymoGenetics' work in the field of recombinant DNA technology and protein therapeutics remains a testament to the potential of biotechnology to address unmet medical needs.

See Also

• Biotechnology
• Recombinant DNA
• Therapeutic proteins
• Bristol-Myers Squibb